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Background: Breast cancer is the leading cause of cancer-related mortality in women 
worldwide. Since a significant portion of cases present with or progress to metastatic 
disease, furthering our understanding of metastasis is critical to develop better treatments. 
Epithelial cells maintain contact with the extracellular matrix (ECM) predominantly via 
integrin engagement, a process required for tissue integrity and barrier function. In non-
transformed cells, loss of ECM adhesion promotes a specialized form of programmed cell 
death, anoikis. In order for efficient metastasis to occur, breast tumor cells must evade 
anoikis. miR-203, known to be down-regulated in several cancers, was found by our lab 
to be induced ten-fold 24 hours following detachment in breast epithelial cells, but not 
invasive triple negative breast cancer (TNBC) cells, suggesting that miR-203 may 
participate in promoting anoikis. Interestingly, more invasive breast cancer cell lines have 
been shown to express miR-203 at significantly lower levels than those of less invasive 
lines. 
 
Objectives: Since restoration of miR-203 expression ectopically is not feasible in a 
clinical setting, we sought to identify and characterize miR-203 target genes in order to 
provide a pharmaceutical platform for restoration of anoikis sensitivity in metastatic 
breast cancer. 
 
Methods: We performed traditional RNA-sequencing (RNA-Seq) coupled with 
immunoprecipitation of the RNA-induced silencing complex (RISC; Ago2 RIP-Seq) in 
MCF-10A, an immortalized, but non-transformed breast epithelial cell line, 
overexpressing precursor miR-203 or an empty vector control. MDA-MB-231, triple 
negative ductal carcinoma cells, were used as our invasive comparison cell line. 
 
Results: Here we show that miR-203 induction in detached MCF-10A cells is due to loss 
of integrin signaling. Our coupled RNA-Seq and Ago2 RIP-Seq approach revealed 72 
potential candidates, 42 of which were predicted miR-203 targets based on the 
TargetScan algorithm. We subjected the candidates to stringent characterization and 
found 9 bona-fide miR-203 targets that promote cell death when inhibited. Among these, 
WDR69, PRKAB1, PRPS2, and HBEGF were significantly elevated in TNBC tumor 
samples, as determined by RNA-Seq analysis in The Cancer Genome Atlas (TCGA). 
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Conclusion: Understanding the mechanisms by which cells evade anoikis during tumor 
dissemination is crucial to developing more effective therapies in breast cancer. miR-203, 
which is expressed at very low levels in more invasive breast cancers, is a positive 
regulator of anoikis that is upregulated in response to loss of contact with the ECM. Our 
combined RNA-sequencing screen revealed 42 direct miR-203 targets. Inhibition of 9 
bona-fide targets promoted cell death, suggesting that they are negative regulators of 
anoikis. WDR69, PRKAB1, PRPS2, and HBEGF were all significantly elevated in 
TNBC tumor samples relative to less invasive samples, likely a consequence of low miR-
203 expression. The identified genes represent potential pharmaceutical targets for novel 
breast cancer therapies. 
 
